Halozyme Therapeutics, Inc. (FRA:RV7)

Halozyme Therapeutics Revenue

Halozyme Therapeutics had revenue of $354.26M USD in the quarter ending September 30, 2025, with 22.12% growth. This brings the company's revenue in the last twelve months to $1.24B, up 31.19% year-over-year. In the year 2024, Halozyme Therapeutics had annual revenue of $1.02B with 22.44% growth.

• Revenue (ttm): $1.24B
• Revenue Growth: +31.19%
• P/S Ratio: 6.84
• Revenue / Employee: $3.55M
• Employees: 350
• Market Cap: 7.24B EUR

Revenue Chart

* This company reports financials in USD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	1.02B	186.07M	22.44%
Dec 31, 2023	829.25M	169.14M	25.62%
Dec 31, 2022	660.12M	216.81M	48.91%
Dec 31, 2021	443.31M	175.72M	65.67%
Dec 31, 2020	267.59M	71.60M	36.53%
Dec 31, 2019	195.99M	44.13M	29.06%
Dec 31, 2018	151.86M	-164.75M	-52.04%
Dec 31, 2017	316.61M	169.92M	115.84%
Dec 31, 2016	146.69M	11.63M	8.61%
Dec 31, 2015	135.06M	59.72M	79.28%
Dec 31, 2014	75.33M	20.54M	37.47%
Dec 31, 2013	54.80M	12.47M	29.47%
Dec 31, 2012	42.33M	-13.76M	-24.54%
Dec 31, 2011	56.09M	42.46M	311.67%
Dec 31, 2010	13.62M	-47.19K	-0.35%
Dec 31, 2009	13.67M	4.91M	55.99%
Dec 31, 2008	8.76M	4.96M	130.66%
Dec 31, 2007	3.80M	-977.95M	-99.61%
Dec 31, 2006	981.75M	854.54M	671.76%
Dec 31, 2005	127.21M	-	-